NASDAQ:ATXI Avenue Therapeutics (ATXI) Stock Forecast, Price & News $0.69 -0.02 (-2.82%) (As of 10/2/2023 ET) Add Compare Share Share Today's Range$0.63▼$0.7150-Day Range$0.56▼$1.1252-Week Range$0.54▼$16.65Volume82,943 shsAverage Volume433,856 shsMarket Capitalization$5.64 millionP/E RatioN/ADividend YieldN/APrice Target$32.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Avenue Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside4,537.7% Upside$32.00 Price TargetShort InterestHealthy0.45% of Float Sold ShortDividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews Sentiment0.43Based on 2 Articles This WeekInsider TradingAcquiring Shares$552,301 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.12 out of 5 stars 3.5 Analyst's Opinion Consensus RatingAvenue Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.00, Avenue Therapeutics has a forecasted upside of 4,537.7% from its current price of $0.69.Amount of Analyst CoverageAvenue Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.45% of the float of Avenue Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvenue Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avenue Therapeutics has recently increased by 184.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvenue Therapeutics does not currently pay a dividend.Dividend GrowthAvenue Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAvenue Therapeutics has received a 73.16% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Avenue Therapeutics is -0.99. Previous Next 1.4 News and Social Media Coverage News SentimentAvenue Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Avenue Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for ATXI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avenue Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $552,301.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.35% of the stock of Avenue Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 9.38% of the stock of Avenue Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Avenue Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avenue Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvenue Therapeutics has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Avenue Therapeutics (NASDAQ:ATXI) StockAvenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.Read More ATXI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATXI Stock News HeadlinesSeptember 8, 2023 | msn.comManchester police investigate stabbing at 7-Eleven on Queen City AvenueSeptember 8, 2023 | msn.com3 women sexually assaulted near Whyte Avenue while walking alone last weekend: Edmonton policeOctober 3, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 7, 2023 | msn.comHeavy police presence seen on Asylum Avenue in HartfordSeptember 6, 2023 | msn.comSneak peek at historic Summit Avenue condo — with a turret! — going up for sale ThursdaySeptember 6, 2023 | msn.com1 person shot this morning in Syracuse off Teall Avenue, deputies saySeptember 6, 2023 | msn.comMan hospitalized after hit-and-run on Lamar AvenueSeptember 5, 2023 | finance.yahoo.comAvenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment ConferenceOctober 3, 2023 | Stansberry Research (Ad)Are "The Magnificent Seven" the Next Sears?The former retail giant’s sales once accounted for 1% of the U.S. economy. Now it’s nearly extinct. Will the same happen to big tech? Learn more here.September 5, 2023 | msn.comOne person killed in Lexington Avenue crash overnightSeptember 4, 2023 | msn.comReported crash with injuries on Hulbert Avenue in ErlangerSeptember 3, 2023 | msn.com17-year-old in critical condition after shooting on Bickford Avenue , police saySeptember 3, 2023 | msn.comI-10 eastbound closed at 83rd Avenue due to police situationAugust 26, 2023 | abcnews.go.comSee Ariana Grande perform 'Honeymoon Avenue' to celebrate 10 years of 'Yours Truly,' her debut albumAugust 18, 2023 | msn.comMet Council delays Summit Avenue bikeway vote as opponents petition for environmental reviewAugust 18, 2023 | msn.comCity accepts $8M grant to redesign University Avenue and make it saferAugust 17, 2023 | msn.comDC police involved in shooting on Georgia AvenueAugust 17, 2023 | msn.comDeadly house fire on Dodson AvenueAugust 17, 2023 | msn.comMan and woman dead after shooting on Longacre Avenue, police sayAugust 16, 2023 | msn.comOne person killed in car accident on MacCorkle AvenueAugust 16, 2023 | msn.comOfficer shot by suspect on Auzerais Avenue in San Jose, police respondingAugust 16, 2023 | msn.comInside Via Triozzi, the long-awaited Italian restaurant on Dallas’ Greenville AvenueAugust 15, 2023 | msn.comCrash near 7th Avenue and I-10 overpass causes road closuresAugust 15, 2023 | msn.comWoman critically hurt after road rage shooting near I-10 & 91st AvenueAugust 15, 2023 | msn.comFood + Beer prepares to open Lakeland restaurant Aug. 21 off South Florida AvenueAugust 15, 2023 | msn.comHeavy police presence seen on Berkshire Avenue in SpringfieldAugust 14, 2023 | msn.comDeadly hit and run shuts down part of West Central Avenue in Mount HollySee More Headlines Receive ATXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATXI Company Calendar Last Earnings8/10/2023Today10/02/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATXI CUSIPN/A CIK1644963 Webwww.avenuetx.com Phone(781) 652-4500FaxN/AEmployees2Year Founded2015Price Target and Rating Average Stock Price Forecast$32.00 High Stock Price Forecast$32.00 Low Stock Price Forecast$32.00 Forecasted Upside/Downside+4,537.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,550,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,988.73% Return on Assets-266.83% Debt Debt-to-Equity RatioN/A Current Ratio0.21 Quick Ratio0.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book1.08Miscellaneous Outstanding Shares8,180,000Free Float8,154,000Market Cap$5.64 million OptionableNot Optionable Beta-0.36 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Alexandra MacLean M.D. (Age 55)CEO & Director Comp: $515.56kMr. David Jin (Age 32)Interim CFO, COO & Corp. Sec. Dr. Lindsay Allan Rosenwald (Age 68)Exec. Director Dr. Xiaoqin Lu M.D. (Age 48)Consultant Comp: $1.05MDr. Scott A. Reines M.D. (Age 76)Ph.D., Interim Chief Medical Officer Mr. Srinivas Subramanian (Age 52)Exec. VP More ExecutivesKey CompetitorsAddex TherapeuticsNASDAQ:ADXNNexImmuneNASDAQ:NEXIQualigen TherapeuticsNASDAQ:QLGNPaxMedicaNASDAQ:PXMDBenitec BiopharmaNASDAQ:BNTCView All CompetitorsInsiders & InstitutionsFortress Biotech, Inc.Bought 418,410 shares on 9/8/2023Total: $301,255.20 ($0.72/share)Lindsay A Md RosenwaldBought 348,675 shares on 9/8/2023Total: $251,046.00 ($0.72/share)Geode Capital Management LLCBought 41,141 shares on 8/11/2023Ownership: 0.665%View All Insider TransactionsView All Institutional Transactions ATXI Stock - Frequently Asked Questions Should I buy or sell Avenue Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATXI shares. View ATXI analyst ratings or view top-rated stocks. What is Avenue Therapeutics' stock price forecast for 2023? 1 Wall Street research analysts have issued 1 year target prices for Avenue Therapeutics' shares. Their ATXI share price forecasts range from $32.00 to $32.00. On average, they anticipate the company's stock price to reach $32.00 in the next twelve months. This suggests a possible upside of 4,537.7% from the stock's current price. View analysts price targets for ATXI or view top-rated stocks among Wall Street analysts. How have ATXI shares performed in 2023? Avenue Therapeutics' stock was trading at $1.16 at the start of the year. Since then, ATXI shares have decreased by 40.5% and is now trading at $0.69. View the best growth stocks for 2023 here. Are investors shorting Avenue Therapeutics? Avenue Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 26,700 shares, an increase of 184.0% from the August 31st total of 9,400 shares. Based on an average daily trading volume, of 70,100 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.5% of the company's shares are sold short. View Avenue Therapeutics' Short Interest. When is Avenue Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our ATXI earnings forecast. How were Avenue Therapeutics' earnings last quarter? Avenue Therapeutics, Inc. (NASDAQ:ATXI) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.52) EPS for the quarter. When did Avenue Therapeutics' stock split? Shares of Avenue Therapeutics reverse split before market open on Friday, September 23rd 2022. The 1-15 reverse split was announced on Friday, September 23rd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Avenue Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avenue Therapeutics investors own include Gilead Sciences (GILD), AbbVie (ABBV), Fulcrum Therapeutics (FULC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), CymaBay Therapeutics (CBAY), CytomX Therapeutics (CTMX) and Spero Therapeutics (SPRO). When did Avenue Therapeutics IPO? (ATXI) raised $30 million in an initial public offering (IPO) on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager. What is Avenue Therapeutics' stock symbol? Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI." How do I buy shares of Avenue Therapeutics? Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avenue Therapeutics' stock price today? One share of ATXI stock can currently be purchased for approximately $0.69. How much money does Avenue Therapeutics make? Avenue Therapeutics (NASDAQ:ATXI) has a market capitalization of $5.64 million. The company earns $-3,550,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. How can I contact Avenue Therapeutics? Avenue Therapeutics' mailing address is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. The official website for the company is www.avenuetx.com. The company can be reached via phone at (781) 652-4500 or via email at ir@avenuetx.com. This page (NASDAQ:ATXI) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.